Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 13, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: February 9, 2007
- Previous Holdings: 16,417,421 ADRs
- New Holdings: 16,417,793 ADRs
- Net Change: Increase of 372 ADRs
- Average Price: $55.84
The change resulted from a movement in the fund. The Plan is a discretionary fund for employees and former employees. Directors Dr. J.P. Garnier and Dr. M.M. Slaoui are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses the notification of the transaction under Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of ADRs held by the US Retirement Savings Plan as of February 9, 2007 (16,417,793).
- Confirm the average transaction price of $55.84 for the fund movement.
- Note that the increase in holdings was due to fund movement, not direct director trading.
- Recognize that Directors Dr. Garnier and Dr. Slaoui have a potential interest in these shares only as beneficiaries of the employee plan.